Seeking Alpha
Profile| Send Message|
( followers)  

Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on biotechnology and drugs stocks that have earnings due in the next week. This article provides earnings previews on several stocks to consider in anticipation of their earnings reports. Use this list as a potential starting point for your analysis.

Watson Pharmaceuticals, Inc. (WPI): April 30, 2012

Watson is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. The company operates in three segments: Global Generics, Global Brands and Distribution.

Watson has a market cap of $8.833 billion and will report its first quarter earnings results on April 30, 2012, before market open. The first quarter revenues are expected to be $1.48 billion when compared to $876.50 million for the same quarter last year. Earnings per share for the first quarter are expected to be $1.60 a share from 89 cents a share in the year ago period. Watson is currently trading around $69.46 with a 52 week range of $55.00 to $73.35.

NuVasive, Inc. (NUVA): April 30, 2012

NuVasive is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine.

NuVasive has a market cap of $683.3 million and will report its first quarter earnings results on April 30, 2012, after market close. The first quarter revenues are expected to be $143.64 million when compared to $124.47 million for the same quarter last year. Earnings per share for the first quarter are expected to be 18 cents a share from 24 cents a share in the year ago period. NuVasive is currently trading around $16.02 with a 52 week range of $11.02 to $34.91.

Biogen Idec Inc. (BIIB): May 1, 2012

Biogen Idec is a global biotechnology company. The company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The company's products include Avonex, Tysabri, Fampyra, Fumaderm and Rituxan.

Biogen Idec has a market cap of $30.044 billion and will report its first quarter earnings results on May 1, 2012, before market open. The first quarter revenues are expected to be $1.31 billion when compared to $1.20 billion for the same quarter last year. Earnings per share for the first quarter are expected to be $1.48 a share from $1.43 a share in the year ago period. Biogen Idec is currently trading around $125.85 with a 52 week range of $83.83 to $130.00.

Pozen Inc. (POZN): May 1, 2012

Pozen is a pharmaceutical company focused on transforming medicine. The company has developed Treximet in collaboration with GlaxoSmithKline (NYSE:GSK).

Pozen has a market cap of $231.1 million and will report its first quarter earnings results on May 1, 2012, before market open. The first quarter revenues are expected to be $1.27 million when compared to $4.46 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 25 cents a share from loss of 19 cents a share in the year ago period. Pozen is currently trading around $7.71 with a 52 week range of $2.15 to $7.95.

Impax Laboratories Inc (IPXL): May 1, 2012

Impax is a specialty pharmaceutical company. The company is engaged in development, manufacture and marketing of bio-equivalent pharmaceutical products, referred to as generics, in addition to the development of branded products.

Impax has a market cap of $1.555 billion and will report its first quarter earnings results on May 1, 2012, before market open. The first quarter revenues are expected to be $162.96 million when compared to $108.65 million for the same quarter last year. Earnings per share for the first quarter are expected to be 47 cents a share from 24 cents a share in the year ago period. Impax is currently trading around $23.98 with a 52 week range of $14.46 to $28.75.

Onyx Pharmaceuticals, Inc. (ONXX): May 2, 2012

Onyx Pharmaceuticals is a biopharmaceutical company. The company is developing therapies that target the molecular mechanisms that cause cancer. The company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition.

Onyx Pharmaceuticals has a market cap of $2.784 billion and will report its first quarter earnings results on May 2, 2012, after market close. The first quarter revenues are expected to be $69.82 million when compared to $67.14 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 55 cents a share from loss of 23 cents a share in the year ago period. Onyx Pharmaceuticals is currently trading around $43.45 with a 52 week range of $27.17 to $46.07.

Ligand Pharmaceuticals Inc. (LGND): May 2, 2012

Ligand Pharmaceuticals Inc. (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The company's technology portfolio Captisol is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products.

Ligand Pharmaceuticals Inc. has a market cap of $272.4 million and will report its first quarter earnings results on May 2, 2012, after market close. The first quarter revenues are expected to be $8.02 million when compared to $3.90 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 2 cents a share from 48 cents a share in the year ago period. Ligand Pharmaceuticals Inc. is currently trading around $13.84 with a 52 week range of $9.76 to $18.74.

Momenta Pharmaceuticals, Inc. (MNTA): May 3, 2012

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules

Momenta Pharmaceuticals has a market cap of $769.2 million and will report its first quarter earnings results on May 3, 2012, before market open. The first quarter revenues are expected to be $37.38 million when compared to $78.17 million for the same quarter last year. Earnings per share for the first quarter are expected to be 21 cents a share from $1.13 a share in the year ago period. Momenta Pharmaceuticals is currently trading around $15.33 with a 52 week range of $10.15 to $21.00.

Synta Pharmaceuticals Corp. (SNTA): May 3, 2012

Synta Pharmaceuticals Corp. is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases.

Synta Pharmaceuticals has a market cap of $200.8 million and will report its first quarter earnings results on May 3, 2012, before market open. The first quarter revenues are expected to be $0.660 million when compared to $1.14 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 25 cents a share from loss of 27 cents a share in the year ago period. Synta Pharmaceuticals is currently trading around $4.06 with a 52 week range of $3.02 to $6.27.

Sources: Some of the data is sourced from Google Finance, Yahoo Finance and investors site.

Disclaimer: I am not a registered investment advisor and do not provide specific investment advice. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. It is up to the investors to make the correct decision after necessary research.

Source: Biotechnology And Drugs Stocks To Watch For Next Week